



Breakout Group: Thrombotic Risk in COVID-19 Patients

Session Lead: **Geoffrey Barnes, MD, MSc, FACC**

Clinical Topics for Consideration:

- ❖ VTE prevention dosing/intensity in hospitalized patients with COVID-19 (ICU and non-ICU)
- ❖ Potential role for anti-platelet therapy to prevent thrombosis in patients with COVID-19
- ❖ Role of post-hospital thromboprophylaxis for COVID-19
- ❖ Role of thromboprophylaxis for non-hospitalized patients with COVID-19
- ❖ Which biomarkers should be checked to assist with risk stratification or treatment decisions in patients with COVID-19?
- ❖ When should CT, Echocardiography, and Vascular Lab imaging be performed/deferred for patients with COVID-19?

Participants:

Jeffrey S. Berger, MD, FACC

Director
Center for the Prevention of CV Disease
NYU Langone Health

Behrood Bikdeli, MD, MS

Vascular Medicine Advanced Fellow
Harvard Medical School

Jean M. Connors, MD

Associate Professor of Medicine
Harvard Medical School

Ricardo Garcia-Sanchez, MD

Head, Eliquis & Thrombosis
Worldwide Medical Cardiovascular
Bristol Myers Squibb

Ty Gluckman, MD, FACC

Medical Director, Center for Cardiovascular
Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence St. Joseph Health

Yogendra Kanthi, MD

Lasker Investigator, Chief - Laboratory of
Vascular Thrombosis & Inflammation
National Heart, Lung and Blood Institute
National Institutes of Health

Jerrold H. Levy, MD

Professor of Anesthesiology, Critical Care, and
Surgery (Cardiothoracic)
Duke University Medical Centre

Gregory Piazza, MD, MS, FACC

Associate Professor of Medicine
Harvard Medical School

Deborah Siegal, MD, MSc, FRCPC

Associate Professor, Department of Medicine
University Of Ottawa and Ottawa Hospital
Research Institute

Leben Tefera, MD

Staff Physician
Cleveland Clinic

Barbara S. Wiggins, PharmD, BCPS, FACC

Affiliate Professor
South Carolina College of Pharmacy
Medical University of South Carolina